DE3888340T2 - Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. - Google Patents

Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.

Info

Publication number
DE3888340T2
DE3888340T2 DE3888340T DE3888340T DE3888340T2 DE 3888340 T2 DE3888340 T2 DE 3888340T2 DE 3888340 T DE3888340 T DE 3888340T DE 3888340 T DE3888340 T DE 3888340T DE 3888340 T2 DE3888340 T2 DE 3888340T2
Authority
DE
Germany
Prior art keywords
insomnia
disubstituted
treatment
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3888340T
Other languages
English (en)
Other versions
DE3888340D1 (de
Inventor
Paul J Schechter
John M Orwin
Christian Karl Hinze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE3888340D1 publication Critical patent/DE3888340D1/de
Application granted granted Critical
Publication of DE3888340T2 publication Critical patent/DE3888340T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02D—CONTROLLING COMBUSTION ENGINES
    • F02D45/00—Electrical control not provided for in groups F02D41/00 - F02D43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Combustion & Propulsion (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE3888340T 1988-01-21 1988-01-21 Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. Expired - Fee Related DE3888340T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88400131A EP0325063B1 (de) 1988-01-21 1988-01-21 Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit

Publications (2)

Publication Number Publication Date
DE3888340D1 DE3888340D1 (de) 1994-04-14
DE3888340T2 true DE3888340T2 (de) 1994-06-30

Family

ID=8200343

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3888340T Expired - Fee Related DE3888340T2 (de) 1988-01-21 1988-01-21 Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.

Country Status (10)

Country Link
US (1) US4908369A (de)
EP (1) EP0325063B1 (de)
JP (1) JP2852933B2 (de)
KR (1) KR890011596A (de)
AT (1) ATE102482T1 (de)
AU (1) AU610972B2 (de)
DE (1) DE3888340T2 (de)
DK (1) DK26289A (de)
IE (1) IE62992B1 (de)
ZA (1) ZA89389B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114467T1 (de) * 1990-06-01 1994-12-15 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol.
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
EP0796619A1 (de) 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
WO2000012090A1 (en) * 1998-08-28 2000-03-09 Aventis Pharmaceuticals Inc. THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US6277864B1 (en) * 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
CN100384836C (zh) * 2000-02-29 2008-04-30 三菱制药株式会社 新型环状酰胺衍生物
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
LT3135286T (lt) * 2010-07-20 2023-11-10 Minerva Neurosciences, Inc. Ciklinio amido darinių panaudojimo būdai, gydant šizofreniją ir jos simptomus
EP3227273B1 (de) 2014-12-02 2022-02-09 Minerva Neurosciences, Inc. Zusammensetzungen enthaltend 2-((1-(2 (4-fluorphenyl ) -2-oxoethyl) piperidin-4-yl) methyl) isoindolin-1-on zur behandlung von schizophrenie
IL308650A (en) 2017-06-21 2024-01-01 Minerva Neurosciences Inc Stomach-resistant controlled-release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1280421C (en) * 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives

Also Published As

Publication number Publication date
US4908369A (en) 1990-03-13
DK26289D0 (da) 1989-01-20
DK26289A (da) 1989-07-22
EP0325063B1 (de) 1994-03-09
AU2868689A (en) 1989-07-27
DE3888340D1 (de) 1994-04-14
KR890011596A (ko) 1989-08-21
ZA89389B (en) 1989-10-25
JPH01279832A (ja) 1989-11-10
AU610972B2 (en) 1991-05-30
EP0325063A1 (de) 1989-07-26
IE62992B1 (en) 1995-03-08
IE890177L (en) 1989-07-21
ATE102482T1 (de) 1994-03-15
JP2852933B2 (ja) 1999-02-03

Similar Documents

Publication Publication Date Title
DE3888340T2 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
DE69104314T2 (de) Verwendung von 1-[3-(Dimethylamino)propyl]-1-phenylphthalenen zur Behandlung zerebrovaskulärer Störungen.
ATE92316T1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE121395T1 (de) Cumarinderivate, ihre herstellung und ihre verwendung zur behandlung von zerebrovaskulären störungen.
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
ATE245986T1 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3- benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ATE121623T1 (de) Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie.
IE800900L (en) Pyrrolidinyl-benzoic acid derivatives.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
DE3884878T2 (de) Uricosuretische Zusammensetzung.
DE3770481D1 (de) Verwendung von imidazochinazolinen zur behandlung und verhinderung von nephritis.
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee